Topic: antibody drug conjugates
Japanese CDMO Ajinomoto Althea is expanding production at its recently completed high-potency products manufacturing facility in San Diego.
Did Daiichi Sankyo receive a buyout bid from AstraZeneca last year? According to the Japanese drugmaker, no.
Japan’s Daiichi Sankyo has been in cost-cutting mode for several years, but says it will invest about $135 million in its manufacturing operations in Japan as its looks to targeted cancer meds to help fuel its future.